|
[1]
|
Despres, J.P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G.R., Moorjani, S. and Lupien, P.J. (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. The New England Journal of Medicine, 334, 952-957. doi:10.1056/NEJM199604113341504
|
|
[2]
|
Voipio-Pulkki, L.M., Nuutila, P., Knuuti, M.J., Ruotsalainen, U., Haaparanta, M., Ter?s, M., Wegelius, U. and Koivisto, V.A.(1993) Heart and skeletal muscle glucose disposal in type 2 diabetic patients as determined by positron emission tomography. Journal of Nuclear Medicine, 34, 2064-2067.
|
|
[3]
|
Yokoyama, I., Ohtake, T., Momomura, S., Yonekura, K., Yamada, N., Nishikawa, J., Sasaki, Y. and Omata, M. (1998) Organ-specific insulin resistance in patients with noninsulin-dependent diabetes mellitus and hypertension. Journal of Nuclear Medicine, 39, 884-889.
|
|
[4]
|
Yokoyama, I., Yonekura, K., Moritan, T., Tateno, M., Momose, T., Ohtomo, K., Inoue, Y. and Nagai, R.(2001) Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients. Journal of Nuclear Medicine, 42, 1005-1010.
|
|
[5]
|
Yokoyama, I., Yonekura, K., Ohtake, T., Kawamura, H., Matsumoto, A., Inoue, Y., Aoyagi, T., Sugiura, S., Omata, M., Ohtomo, K. and Nagai, R. (2000) Role of insulin resistance in heart and skeletal muscle F-18 fluorodeoxy-glucose uptake in patients with non-insulin-dependent diabetes mellitus. Journal of Nuclear Cardiology, 7, 242-248. doi:10.1016/S1071-3581(00)70013-4
|
|
[6]
|
H?llsten, K., Virtanen, K.A., L?nnqvist, F., Janatuinen, T., Turiceanu, M., R?nnemaa, T., Viikari, J., Lehtim?ki, T., Knuuti, J. and Nuutila, P. (2004) Enhancement of insulin- stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabetic Medicine, 21, 1280-1287.
doi:10.1111/j.1464-5491.2004.01332.x
|
|
[7]
|
Lautamaki, R., Airaksinen, K.E., Seppanen, M., Toikka, J., Luotolahti, M., Ball, E., Borra, R., Harkonen, R., Iozzo, P., Stewart, M., Knuuti, J. and Nuutila, P. (2005) Rosigli- tazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: A 16-week randomized, double-blind, placebo-controlled study. Diabetes, 54, 2787-2794.
doi:10.2337/diabetes.54.9.2787
|
|
[8]
|
Naoumova, R.P., Kindler, H., Leccisotti, L., Mongillo, M., Khan, M.T., Neuwirth, C., Seed, M., Holvoet, P., Betteridge, J. and Camici, P.G. (2007) Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: A randomized, double-blind, placebo-controlled study. Jour- nal of the American College of Cardiology, 50, 2059- 2060. doi:10.1016/j.jacc.2007.07.070
|
|
[9]
|
Lincoff, A.M., Wolski, K., Nicholls, S.J. and Nissen, S.E. (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. Journal of the American Medical Association, 298, 1180-1188.
doi:10.1001/jama.298.10.1180
|
|
[10]
|
Barsheshet, A., Shotan, A., Cohen, E., Garty, M., Gold- enberg, I., Sandach, A., Behar, S., Zimlichman, E., Lewis, B.S., Gottlieb, S. and HFSIS Steering Committee and In- vestigators (2010) Predictors of long-term (4-year) mortality in elderly and young patients with acute heart failure. European Journal of Heart Failure, 12, 833-840.
doi:10.1093/eurjhf/hfq079
|
|
[11]
|
Ehrenkaufer, R.E., Potocki, J.F. and Jewett, D.M. (1989) Simple synthesis of F-18 labeled 2-fluoro-2-deoxy-D-glu- cose. Journal of Nuclear Medicine, 25, 333-337.
|
|
[12]
|
Ohtake, T., Kosaka, N., Watanabe, T., Yokoyama, I., Moritan, T., Masuo, M., Iizuka, M., Kozeni, K., Momose, T., Oku, S., Sugimoto, T. and Iio, M. (1991) Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. Journal of Nuclear Medicine, 32, 1432-1438.
|
|
[13]
|
Ng, C.K., Soufer, R. and McNulty, P.H. (1998) Effect of hyperinsulinemia on myocardial fluorine-18-FDG uptake. Journal of Nuclear Medicine, 39, 379-383.
|
|
[14]
|
Kelly, D.E., Williams, K.V. and Goodpaster, B. (1999) Determination of the lumped constant for [18F]fluorodeo- xyglucose in human skeletal muscle. Journal of Nuclear Medicine, 40, 1798-1804.
|
|
[15]
|
Peltoniemi, P., L?nnroth, P., Laine, H., Oikonen, V., Tol- vanen, T., Gr?nroos, T., Strindberg, L., Knuuti, J. and Nuutila, P. (2000) Lumped constant for [18F]fluorodeoxy-glucose in skeletal muscles of obese and nonobese humans. American Journal of Physiology—Endocrinology and Metabolism, 279, E1120-E1130.
|
|
[16]
|
Yokoyama, I., Ohtake, T., Momomura, S., Yonekura, K., Shin, W.S., Nishikawa, J., Sasaki, Y. and Omata, M. (1998) Hyperglycemia rather than insulin resistance is related to coronary flow reserve in patients with non-insulin dependent diabetes mellitus. Diabetes, 47, 119-124.
doi:10.2337/diabetes.47.1.119
|
|
[17]
|
Hsiao, A., Worrall, D.S., Olefsky, J.M. and Subramaniam, S. (2004) Variance-modeled posterior inference of microarray data: Detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics, 20, 3108-3127.
doi:10.1093/bioinformatics/bth371
|
|
[18]
|
Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K., Skene, A.M., Tan, M.H., Lefèbvre, P.J., Murray, G.D., Standl, E., Wilcox, R.G., Wilhelmsen, L., Betteridge, J., Birkeland, K., Golay, A., Heine, R.J., Korányi, L., Laakso, M., Mokán, M., Norkus, A., Pirags, V., Podar, T., Scheen, A., Scherbaum, W., Schernthaner, G., Schmitz, O., Skrha, J., Smith, U. and Taton, J. (2005) Secondary prevention of macrovas- cular events in patients with type 2 diabetes in the PRO- active Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial. Lancet, 366, 1279-1289.
doi:10.1016/S0140-6736(05)67528-9
|
|
[19]
|
Nissen, S.E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine, 356, 2457-2471. doi:10.1056/NEJMoa072761
|
|
[20]
|
Juurlinkm, D.N., Gomes, T., Lipscombe, L.L., Austin, P.C., Hux, J.E. and Mamdani, M.M. (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population based cohort study. British Medical Journal, 339, b2942. doi:10.1136/bmj.b2942
|
|
[21]
|
Graham, D.J., Ouellet-Hellstrom, R., MaCurdy, T.E., Ali, F., Sholley, C., Worrall, C. and Kelman, J.A. (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosi- glitazone or pioglitazone. Journal of the American Medi- cal Association, 3044, 411-418.
doi:10.1001/jama.2010.920
|
|
[22]
|
Nuutila, P., Maeki, M., Laine, H., Knuuti, J., Ruotsalainen, U., Kuotohahiti, M., Haaparanta, M., Solin, O., Jula, A., Koivisto, V.A., Voipio-Pulkki, L.M. and Ykijaeynen, H. (1995) Insulin action on heart and skeletal muscle glucose uptake in essential hypertension. Journal of Clinical Investigation, 96, 1003-1009. doi:10.1172/JCI118085
|
|
[23]
|
Tanaka, T., Itoh, H., Doi, K., Fukunaga, Y., Hosoda, K., Shintani, M., Yamashita, J., Chun, T.H., Inoue, M., Masatsugu, K., Sawada, N., Saito, T., Inoue, G., Nishimura, H., Yoshimasa, Y. and Nakao, K. (1999) Down regulation of peroxisome proliferator-activated receptor gamma expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia, 42, 702-710.
doi:10.1007/s001250051218
|
|
[24]
|
De Vos, P., Lefebvre, A.M., Miller, S.G., Guerre-Millo, M., Wong, K., Saladin, R., Hamann, L.G., Staels, B., Briggs, M.R. and Auwerx, J. (1996) Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. Journal of Clinical Investigation, 98, 1004-1009.
doi:10.1172/JCI118860
|
|
[25]
|
Okuno, A., Tamemoto, H., Tobe, K., Ueki, K., Mori, Y., Iwamoto, K., Umesono, K., Akanuma, Y., Fujiwara, T., Horikoshi, H., Yazaki, Y. and Kadowaki, T. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zuc- ker rats. Journal of Clinical Investigation, 101, 1354-1361.
doi:10.1172/JCI1235
|
|
[26]
|
Yokoyama, I., Inoue, Y., Moritan, T., Ohtomo, K. and Nagai, R. (2006) Myocardial glucose utilisation in type II diabetes mellitus patients treated with sulphonylurea drugs. European Journal of Nuclear Medicine and Molecular, 33, 703-708.
|
|
[27]
|
Yokoyama, I., Ohtake, T., Momomura, S., Yonekura, K., Kobayakawa, N., Aoyagi, T., Sugiura, S., Yamada, N., Ohtomo, K., Sasaki, Y., Omata, M. and Yazaki, Y. (1999) Insulin action on Heart and skeletal muscle FDG uptake in patients with hypertriglyceridemia. Journal of Nuclear Medicine, 40, 1116-1121.
|